Sutro Financial Statements From 2010 to 2026

STRO Stock

USD 15.52 0.92 6.30%

Sutro Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sutro Biopharma's valuation are provided below:

Gross Profit

274.1 M

Profit Margin

(2.05)

Market Capitalization

79.1 M

Enterprise Value Revenue

0.3577

Revenue

105.6 M

We have found one hundred twenty available fundamental trend indicators for Sutro Biopharma, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Sutro Biopharma's current fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 7th of February 2026, Market Cap is likely to grow to about 498.9 M. Also, Enterprise Value is likely to grow to about 315.9 M

Sutro Biopharma Total Revenue

70.98 Million

Check Sutro Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sutro Biopharma's main balance sheet or income statement drivers, such as Net Interest Income of 16.1 M, Interest Income of 53.6 M or Depreciation And Amortization of 6.3 M, as well as many indicators such as Price To Sales Ratio of 1.95, Dividend Yield of 0.0 or PTB Ratio of 3.0. Sutro financial statements analysis is a perfect complement when working with Sutro Biopharma Valuation or Volatility modules.

Build AI portfolio with Sutro Stock

Check out the analysis of Sutro Biopharma Correlation against competitors.

To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.

Sutro Biopharma Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

304.3 M

445.3 M

215 M

Slightly volatile

Short and Long Term Debt Total

29.9 M

26.6 M

18.1 M

Slightly volatile

Other Current Liabilities

53.3 M

50.8 M

15.9 M

Slightly volatile

Total Current Liabilities

159.3 M

151.7 M

66.3 M

Slightly volatile

Other Liabilities

108.7 M

103.5 M

35.9 M

Slightly volatile

Property Plant And Equipment Net

30.5 M

41.2 M

25.5 M

Slightly volatile

Current Deferred Revenue

84.3 M

80.3 M

38.2 M

Pretty Stable

Accounts Payable

6.3 M

12 M

5.3 M

Slightly volatile

Cash

229.8 M

218.8 M

72.1 M

Slightly volatile

Non Current Assets Total

44.2 M

50.5 M

33.7 M

Slightly volatile

Non Currrent Assets Other

7.1 M

9.2 M

4.5 M

Slightly volatile

Other Assets

3 M

3.1 M

9 M

Pretty Stable

Long Term Debt

4.1 M

4.3 M

5.2 M

Slightly volatile

Cash And Short Term Investments

242.6 M

364.4 M

169.2 M

Slightly volatile

Net Receivables

9.9 M

6.1 M

Slightly volatile

Common Stock Shares Outstanding

8.3 M

8.8 M

5 M

Slightly volatile

Long Term Debt Total

11.4 M

18.1 M

8.6 M

Slightly volatile

Liabilities And Stockholders Equity

304.3 M

445.3 M

215 M

Slightly volatile

Non Current Liabilities Total

254.4 M

242.3 M

123.9 M

Slightly volatile

Capital Surpluse

707.9 M

674.2 M

288.3 M

Slightly volatile

Other Current Assets

21.5 M

20.5 M

6.9 M

Slightly volatile

Total Liabilities

413.7 M

394 M

190.2 M

Slightly volatile

Property Plant And Equipment Gross

102 M

97.2 M

40.3 M

Slightly volatile

Preferred Stock Total Equity

82 M

92.3 M

100.7 M

Slightly volatile

Total Current Assets

260.2 M

394.8 M

181.3 M

Slightly volatile

Non Current Liabilities Other

2 M

1.9 M

533.6 K

Slightly volatile

Short Term Debt

10.1 M

8.6 M

7.1 M

Slightly volatile

Common Stock

100.2 K

95.5 K

39.1 K

Slightly volatile

Property Plant Equipment

61.7 M

58.7 M

29.6 M

Slightly volatile

Deferred Long Term Liabilities

1.6 M

1.5 M

867.3 K

Slightly volatile

Short and Long Term Debt

6.2 M

3.7 M

10.1 M

Slightly volatile

Common Stock Total Equity

38 K

52.9 K

32.4 K

Slightly volatile

Capital Stock

53.4 K

95.5 K

39.6 K

Slightly volatile

Sutro Biopharma Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Interest Income

53.6 M

51.1 M

10.3 M

Slightly volatile

Depreciation And Amortization

6.3 M

8.3 M

5.9 M

Slightly volatile

Selling General Administrative

42.6 M

55.7 M

31.5 M

Slightly volatile

Total Revenue

71 M

71.3 M

63.6 M

Slightly volatile

Other Operating Expenses

362.8 M

345.6 M

139.8 M

Slightly volatile

Research Development

304.3 M

289.8 M

107.3 M

Slightly volatile

Cost Of Revenue

6.2 M

6.5 M

35.2 M

Slightly volatile

Total Operating Expenses

354.1 M

337.3 M

132.4 M

Slightly volatile

Income Tax Expense

5.3 M

2.7 M

3 M

Slightly volatile

Reconciled Depreciation

5.9 M

8.3 M

5.4 M

Slightly volatile

Selling And Marketing Expenses

5.5 M

6.1 M

6.7 M

Slightly volatile

Sutro Biopharma Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

15.5 M

28.4 M

10.4 M

Slightly volatile

Begin Period Cash Flow

65.5 M

80.7 M

45.5 M

Slightly volatile

Depreciation

6 M

8.3 M

5.7 M

Slightly volatile

Capital Expenditures

6.2 M

3.6 M

5.1 M

Pretty Stable

End Period Cash Flow

230.8 M

219.8 M

72.6 M

Slightly volatile

Issuance Of Capital Stock

94.6 M

86.9 M

139 M

Slightly volatile

Dividends Paid

393.8 K

532.5 K

356.6 K

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

1.95

2.05

3.2804

Slightly volatile

Days Sales Outstanding

34.5

45.62

28.7854

Slightly volatile

Stock Based Compensation To Revenue

0.38

0.36

0.1646

Slightly volatile

Capex To Depreciation

0.37

0.39

0.8938

Very volatile

Payables Turnover

0.75

0.79

9.3823

Slightly volatile

Sales General And Administrative To Revenue

0.51

0.7

0.495

Slightly volatile

Research And Ddevelopement To Revenue

3.84

3.66

1.6092

Slightly volatile

Capex To Revenue

0.0772

0.0449

0.0842

Very volatile

Cash Per Share

45.06

47.43

478

Slightly volatile

Days Payables Outstanding

501

477

161

Slightly volatile

Current Ratio

3.72

2.34

3.1692

Slightly volatile

Receivables Turnover

7.87

8.28

48.7354

Slightly volatile

Capex Per Share

0.44

0.46

41.9506

Slightly volatile

Revenue Per Share

8.82

9.29

569

Slightly volatile

Interest Debt Per Share

13.72

8.12

17.4312

Slightly volatile

Debt To Assets

0.12

0.0688

0.0761

Slightly volatile

Operating Cycle

34.5

45.62

28.7854

Slightly volatile

Days Of Payables Outstanding

501

477

161

Slightly volatile

Ebt Per Ebit

1.05

1.09

1.0715

Slightly volatile

Long Term Debt To Capitalization

0.0187

0.0196

0.0551

Slightly volatile

Quick Ratio

3.72

2.34

3.1692

Slightly volatile

Net Income Per E B T

1.19

1.16

1.0497

Slightly volatile

Cash Ratio

1.34

1.3

1.1249

Slightly volatile

Days Of Sales Outstanding

34.5

45.62

28.7854

Slightly volatile

Fixed Asset Turnover

3.16

1.99

2.9507

Slightly volatile

Debt Ratio

0.12

0.0688

0.0761

Slightly volatile

Price Sales Ratio

1.95

2.05

3.2804

Slightly volatile

Asset Turnover

0.18

0.1602

0.5325

Slightly volatile

Sutro Biopharma Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

498.9 M

296.8 M

334 M

Slightly volatile

Enterprise Value

315.9 M

200.2 M

235.5 M

Slightly volatile

Sutro Fundamental Market Drivers

	Forward Price Earnings	10.0301
	Cash And Short Term Investments	316.9 M

Sutro Upcoming Events

	4th of April 2024 Upcoming Quarterly Report	View
	20th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	4th of April 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Sutro Biopharma Financial Statements

Sutro Biopharma investors utilize fundamental indicators, such as revenue or net income, to predict how Sutro Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	80.3 M	84.3 M
Total Revenue	71.3 M	71 M
Cost Of Revenue	6.5 M	6.2 M
Stock Based Compensation To Revenue	0.36	0.38
Sales General And Administrative To Revenue	0.70	0.51
Research And Ddevelopement To Revenue	3.66	3.84
Capex To Revenue	0.04	0.08
Revenue Per Share	9.29	8.82
Ebit Per Revenue	(4.42)	(4.20)

Pair Trading with Sutro Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Sutro Stock

0.74

ENGN

enGene Holdings Common

Pair Corr

Moving against Sutro Stock

0.93	ABP	Abpro Holdings	Pair Corr
0.86	DWTX	Dogwood Therapeutics	Pair Corr
0.86	KURA	Kura Oncology	Pair Corr
0.76	LYRA	Lyra Therapeutics	Pair Corr
0.71	GNLX	Genelux Common	Pair Corr

The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.

The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Sutro Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sutro Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sutro Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sutro Biopharma Stock:

How To Invest In Sutro

Details

Is Sutro Stock a good investment?

Details

What is Sutro Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Sutro Biopharma Correlation against competitors.

To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(2.60)

Revenue Per Share

1.261

Quarterly Revenue Growth

0.138

Return On Assets

(0.26)

Return On Equity

(18.10)

Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.

Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Sutro Financial Statements From 2010 to 2026

Sutro Biopharma Total Revenue

70.98 Million

Sutro Biopharma Balance Sheet

Sutro Biopharma Income Statement

Sutro Biopharma Cash Flow Statement

Financial Ratios

Sutro Biopharma Valuation Data

Sutro Fundamental Market Drivers

Sutro Upcoming Events

About Sutro Biopharma Financial Statements

Pair Trading with Sutro Biopharma

Moving together with Sutro Stock

Moving against Sutro Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY